

Akronym/Firma	Substanz	Phase	Indikation	Beschreibung	Rekrutierung
<u>IPF und PF-ILD STUDIEN</u>					
Modern IST 07 / Modern Biosciences	MBS2320	II	Idiopathische Lungenfibrose	A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Investigate the Efficacy and Safety of MBS2320 in Patients With Idiopathic Pulmonary Fibrosis	On Hold
Moonscape GB 44496 / Genentech	Vixarelimab	II	Idiopathische Lungenfibrose / SSc-ILD	A two-cohort, Phase II, multicenter, randomized, double-blind, parallel-group, placebo-controlled study evaluating the efficacy and safety of vixarelimab compared with placebo in patients with idiopathic pulmonary fibrosis and in patients with systemic sclerosis-associated interstitial lung disease.	Aktiv
Tefibeos / Astra Zeneca	Tezepelumab	II	PF-ILD	A prospective two-armed, phase II clinical multicentre randomized, placebocontrolled (2:1), blinded with open-label extension	Aktiv
IM027068 / IM0271015 Bristol Myers Squibb Company	BMS-986278	III	Idiopathische Lungenfibrose / PPF	A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants with Idiopathic Pulmonary Fibrosis / A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants with Progressive Pulmonary Fibrosis	Aktiv
Beacon IPF / Pliant	Bexotegrast	IIb	Idiopathische Lungenfibrose	A randomized, double-blind, dose-ranging, placebo-controlled study to evaluate the efficacy and safety of PLN-74809 (bexotegrast) for the treatment of idiopathic pulmonary fibrosis (BEACON-IPF)	Aktiv
Transform 220929 / Glaxo Smith Kline	GSK3915393	II	Idiopathische Lungenfibrose	A Phase 2, randomized, double-blind, placebo-controlled, parallel group study (TRANSFORM) to evaluate the efficacy and safety of GSK3915393 in participants with Idiopathic Pulmonary Fibrosis (IPF)	Aktiv

BEconneCTD-ILD 221672 / Glaxo Smith Kline	GSK1550188	III	CTD-ILD	A Phase 3, randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of belimumab administered subcutaneously in adults with interstitial lung disease (ILD) associated with connective tissue disease (CTD).	Aktiv
Avalyn-MIST	AP01-007	IIb	PPF	A Randomized, Double-Blind, Placebo-Controlled, Phase 2b Study Evaluating the Safety and Efficacy of Pirfenidone Solution for Inhalation (AP01) in Subjects with Progressive Pulmonary Fibrosis (PPF)	Aktiv
<u>Husten bei Lungenfibrose</u>					
Coral NAL 03-202 / Trevi Therapeutics	Nalbuphine	IIb	Idiopathische Lungenfibrose	A Randomized, Double-Blind, Placebo-Controlled, Parallel, 4-Arm Dose Ranging Study of the Safety and Efficacy of Nalbuphine Extended-Release Tablets (NAL ER) for the Treatment of Cough in Idiopathic Pulmonary Fibrosis (IPF).	Aktiv
Boehringer-Ingelheim	1490-0004	IIa/IIb	Idiopathische Lungenfibrose	A Phase IIa/IIb, randomised, double blind, placebo-controlled, parallel-group dose-finding study to examine the efficacy and safety of BI 1839100 administered orally over a 12-week treatment period in patients with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis with clinically meaningful cough	Aktiv

Sarkoidose STUDIEN

OATD-01-C03 / Molecule Kite Study	CHIT 1	II	Sarkoidose	A randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of a 12-week administration of OATD-01, an oral inhibitor of chitinase- 1 (CHIT1), for the treatment of active pulmonary sarcoidosis (the KITE study)	In Vorbereitung
<u>Beobachtungsstudien / Registerstudien</u>					
Insight-ILD / Boehringer-Ingelheim / GWD	INSIGHTS-ILD Register	NA	Idiopathische Lungenfibrose	INvestigating SIGnificant Health TrendS in Progressive Fibrosing Interstitial Lung Disease	Aktiv